Chapters: 00:00 Intro & Hair Talk 01:01 Podcast Growth & Mission 03:04 Discipline & Six Pack Mindset 06:36 Sobriety, Learning & Growth 08:22 Fear of Failure vs Growth 10:42 Celebrating Hard Work 11:50 GLP-1 Breakdown (Basics) 14:57 How GLP-1 Works (Fat Loss) 19:59 Semaglutide Explained 22:30 Tirzepatide Explained 24:30 Retatrutide Explained 29:01 Dosage & Protocols 34:48 Side Effects & Relationships 40:10 Which One Should You Take 42:14 Lifestyle Still Matters We cover: How GLP-1 peptides actually work GLP-1 is a naturally occurring hormone that signals fullness Normally lasts 510 minutes after eating These compounds extend that signal to days instead of minutes Reduce hunger, slow gastric emptying, and regulate blood sugar The 3 receptors explained (simple + real) GLP-1 signals fullness, reduces food noise GIP improves insulin efficiency, reduces nausea, enhances fat usage Glucagon (GCG) increases metabolism, burns fat, prevents plateaus Semaglutide (Ozempic / Wegovy) GLP-1 only (full activation) Strong appetite suppression High nausea for many users Fat + muscle loss (indiscriminate) ~1517% average weight loss Skinny but feel like shit effect if not eating properly Tirzepatide (Mounjaro / Zepbound) GLP-1 + GIP Much less nausea than semaglutide Better insulin function better nutrient partitioning Less muscle loss ~2022% average weight loss Still suppresses appetite heavily Retatrutide (The King) GLP-1 + GIP + Glucagon (triple agonist) Minimal to no nausea Burns fat directly through metabolism increase Preserves muscle much better Prevents metabolic slowdown (plateau killer) ~24%+ weight loss in trials You still eat just get full faster Why people feel different on each Appetite suppression is actually a side effect, not the goal Semaglutide/Tirzepatide = suppress hunger aggressively Retatrutide = removes food noise but lets you eat normally Better long-term relationship with food Big misconception (IMPORTANT) Hair loss, fatigue, etc
Researchers have been particularly interested in how TB-500 could serve as a simplified model to study cellular motility, tissue organization, and responses to external stimuli
471 According to the PAKT trial, the addition of the AKT inhibitor capivasertib to the first-line paclitaxel therapy for TNBC resulted in significantly longer PFS and OS, especially in tumors with PIK3CA/AKT1/PTEN alterations
If you have any questions or any topics or stories you'd like covered, drop us an email: [email protected]
Patients should discuss their weight loss goals and expectations with their healthcare provider to ensure that they are on track to achieve the desired outcomes
